pmid,title,abstract,journal,pubdate,year,month,day,authors,rochester_authors,affiliations,authors_display,url,llm_summary
41260234,"What is debridement, antibiotics, and implant retention in orthopaedic oncology? : a global cross-sectional survey of surgeons' practices and opinions.","Following resection of a primary bone tumour, reconstruction is commonly performed using either a megaprosthesis or biological reconstruction. Periprosthetic joint infection (PJI) remains one of the most frequent complications. Various treatment strategies exist for PJI, including debridement, antibiotics, and implant retention (DAIR), and single- and two-stage revision, although consensus on optimal management remains elusive. This study aimed to investigate the global practices regarding DAIR in tumour cases through an electronic survey among orthopaedic oncology surgeons.A global cross-sectional observational survey study was distributed to 272 orthopaedic oncology surgeons who attended the BOOM Consensus Meeting in January 2024. The survey contained 19 multiple choice questions focusing on DAIR practices. Responses were collected anonymously and analyzed using descriptive statistics.The survey was completed by 173/272 surgeons (64%) from 44 countries. While 62% (169/272) routinely performed radical soft-tissue debridement in DAIR, only 39% exchanged all modular components, indicating variability in surgical approaches. DAIR was more commonly performed in acute rather than chronic infections, with 55% finding it very useful in acute cases. The use of local antibiotic delivery was supported by 56%, although only 49% found antibiotic cement coatings beneficial. Systemic antibiotic duration post-DAIR varied, with 39% favouring six weeks and 35% preferring three months.The study highlights global inconsistencies in DAIR practices for PJI in orthopaedic oncology, with financial disparities impacting modular component exchange. Standardized definitions are lacking, and we propose that if only polyethylene is changed, then the procedure is referred to as 'poly exchange'; we recommend defining the procedure as DAIR when extensive debridement, lavage, and removal, wash, and reimplanting of all modular components is done while retaining stable stems, followed by suppressive antibiotic therapy; and finally, we recommend that if all the modular components are changed for new ones, the procedure is referred to as 'DAIR plus'.© 2025 Khan et al.",Bone & joint open,"Nov 20, 2025",2025,Nov,20,Khan Z|Khan Z A|Zamorra T|Gulia A|Lozano-Calderon S A|Kurisunkal V J|Jeys L M|Laitinen M K|Abad Repiso S|Abdelbary H|Abiad Mejia A|Abood A A|Abou-Nouar G|Abril Martin J C|Abu Elhamd A|Abudu A|Acosta M|Ae K|Agarwal M|Ajit Singh V|Akiyama T|Albergo J I|Alexander J|Alfaro P A|Alpan B|Alshaygy I|Amaya-Valero J|Anderson M|Andreou D|Annabell L|Anthony C|Aoude A|Arteagoitia-Colino I|Asavamongkolkul A|Aston W|Asua Mentxaka L|Azzopardi C|Baad-Hansen T|Badr I T|Baixauli-Garcia F|Baker G|Balach T|Baldi G G|Barry J|Basile G|Bastoni S|Basuki M H|Bauer H|Bayliss L|Becker R G|Bedi A|Benevenia J|Bengoa F|Bergh P|Bergovec M|Bernthal N|Binitie O|Boddie D|Boffano M|Bonilla Huertas P|Borgognoni A B|Botchu R|Bramer J|Branford-White H|Brar R|Broekhuis D|Broida S E|Budny T|Burke Z D|Cabrolier J|Calvo Tapies J R|Calvo-Haro J A|Campanacci D|Cardoso R|Carey Smith R|Carvallo P I|Casales Fresenga N|Casanova J M|Ceballos O|Cebrian Parra J L|Certain L K|Chacon Cartaya S|Chan C M|Cho Y|Choong P|Chung Y|Ciechanowicz D|Clara-Altamirano M A|Clever D|Colina S M|Consuegra L|Couch C|Cribb G|Cuervo C|Cusick L A|Dadia S|Dagher T|Dammerer D|Davies M|Davies N|de la Rosa Martino L P|de Santos de la Fuente F J|de Vaal M|Deckers C|Delgado Obando J|Deo S|Deventer N|Di Bella C|Domson G|Donati D M|Dorleijn D M|Du Toit J|Dunne D|Duran Ciarrochi R|Ekman E|El Ghoneimy A M|Endo M|Eralp L|Etaiwi M|Evans S|Evrard R|Eward W|Farese A|Ferguson P C|Ferreira Cardoso P F|Fiorenza F|Flint M|Flores H|Freitas J|Fuchs B|Fujiwara T|Funovics P T|Galli Serra M|Gamie Z|Garces-Zarzalejo C|Gazendam A|Gebert C|Gerbers J G|Gerrand C|Ghert M|Ghosh K M|Gibbons M|Gomez-Mascard A|Gomez-Mier L C|Gomez-Vallejo J|Gonzalez M R|Gonzalez-Lizan F|Gosheger G|Goudie S|Goulding K|Goumenos S D|Griffin A|Gulia A|Gupta S|Gupta A|Guzman M|Haitham M|Hardes J|Hardoy F|Hasan Y|Hauer G|Havard H|Haydon R|Healey J|Hernandez Gonzalez N|Hernandez-Lopez A|Hesla A|Hess M|Hilton T|Hongsaprabhas C|Hornicek F|Hosking K|Houghton E|Idowu O K|Ippolito J|Isler M|Iwata S|Jagiello J|Jenkins N|Jeys T|Jeys C|Johnson L|Johnston A|Joo M|Jutte P C|Kaldas K|Kamat A|Kannan S|Kapanci B|Khan Z|Kobayashi H|Kollender Y|Koob S|Kotrych D|Kyte R|Lamo de Espinosa Vazquez de Sola J M|Lazarides A L|Le Nail L|Legosz P|Lehner B|Leithner A|Lejoly M|Lewis V O|Lin P|Linares F|Lozano-Calderon S|Mahendra A|Mahyudin F|Mandia Mancebo F J|Martos Torrejon S|Marx C|Mascard E|Mattei J|McCullough L|McMahon S|Medellin Rincon M R|Miller B|Miwa S|Molina Uribe G|Moon B|Moriel Garcesco D J|Morris C|Morrison S|Mottard S|Moura M|Muster L|Nakayama R|Narhari P|Navas A|Nayak P|Neugebauer J|Newman E T|Nieminen J|Nyqvist E|Nystrom L|O'Reilly-Harbidge S|O'Toole G|Oliveira V|Olivier A|Omar M|Ortiz-Cruz E J|Ozger H|Ozkan K|Pala E|Palmerini E|Pang G|Papagelopoulos P|Paraliticci G|Parry M C|Patton S|Peake D|Peiro Ibanez A|Perez Munoz I|Perianayagam G R|Petersen M M|Ploegmakers J|Pollock R|Powell G|Pretell J|Puetzler J|Qamar F|Raja A|Rajasekaran R B|Ramkumar D B|Randall R L|Rankin K S|Raskin K A|Rassppan K|Repsa L|Ropars M|Rose P|Sadek W|Salcedo G|Saleemi A|Sambri A|Sar H|Scanferla R|Schubert T|Schwarze J|Scoccianti G|Scrimshire A|Sekita T|Shehadeh A|Shoaib A|Shreemal B|Shumelinsky F|Siegel G|Silveri C|Silverwood R|Sinnaeve F|Sison J|Slade A|Smolle M A|Snyman F|Sommerville S|Sood S|Spiguel A|St-Yves H|Staals E L|Stacchiotti S|Stavropoulos N|Steadman P|Stevenson J D|Sullivan M|Sys G|Szostakowski B|Tamburini A|Taniguchi Y|Temple T|Theil C|Thorkildsen J|Tibbo M|Tillman R|Toda Y|Tootsi K|Torner Rubies F|Traub F|Trikoupis I|Tsagkozis P|Tsoi K|Tsuchiya H|Vainio V|Valcarcel A|Valencia J|Van Beeck A|Van de Sande M|Van Den Berghe T|Van der Geest I|Van der Heijden L|Van der Wal R|Van Langevelde K|Vaz G|Velez Villa R|Verspoor F|Verstraete K|Visgauss J|Vyrva O|Wafa H|Walter S|Wan Ismail W F|Wang E|Wang P Q|Warnock D|Werier J|Weschenfelder W|Wong K|Woulthuyzen-Bakker M|Wunder J|Wysinghe I|Yamamoto N|Ye Z|Yoon S|Zainul Abidin S|Zamora T|Zecchetto P|Zhang L|Zumarraga J P,Broida S E|Couch C|Goulding K|Rose P|Sullivan M|Tibbo M,"Department of Orthopedic Surgery, Rehman Medical Institute, Peshawar, Pakistan.|Medical Affairs Department and PharmEvo Research Forum, PharmEvo Pvt. Ltd, Karachi, Pakistan.|Pontificia Universidad Catolica de Chile, Santiago, Chile.|Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh, India.|Musculoskeletal Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA.|Royal Orthopaedic Hospital, Birmingham, UK.|Department of Orthopedics and Traumatology, Helsinki University Central Hospital, Helsinki, Finland.|Hospital Marques de Valdecilla, Cantabria, Spain.|The Ottawa Hospital, Ottawa, Canada.|Clinica Somer, Clinica Vida, Clinica del Campestre, Medellin, Colombia.|Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.|Jordanian Medical Services, Amman, Jordan.|Hospital Del Nino Jesus Madrid, Madrid, Spain.|Orthopaedic Department, Cairo University, Cairo, Egypt.|Instituto Anatomopatologico 'Dr Jose A O'Daly Universidad Central de Venezuela/Laboratorio de Patología Marín, Stato Miranda, Venezuela.|Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.|Nanavati Max Superspeciality Hospital, Mumbai, India.|National Orthopaedic Centre of Excellence in Research & Learning (NOCERAL), Department of Orthopaedic Surgery, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.|Saitama Medical Center, Jichi Medical University, Saitama, Japan.|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.|The James Cancer Hospital, Columbus, Ohio, USA.|Universidad de Concepción, Concepcion, Chile.|Acibadem Maslak Hospital, Istanbul, Turkey.|Department of Orthopaedics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.|Hospital La Fe Valencia, Valencia, Spain.|Boston Children's Hospital / Harvard Medical School, Boston, Massachusetts, USA.|University Hospital of Essen, Essen, Germany.|The Royal Children's Hospital, Melbourne, Victoria, Australia.|Royal National Orthopaedic Hospital, London, UK.|McGill University, Montreal, Canada.|Cruces University Hospital, Barakaldo, Spain.|Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.|Royal National Orthopaedic Hospital, Stanmore, UK.|Hospital Universitario Cruces - Bizkaia, Bizkaia, Spain.|Aarhus University Hospital, Aarhus, Denmark.|Menoufia University, Menoufia, Egypt.|Musgrave Park Hospital, Belfast, UK.|The University of Chicago, Chicago, Illinois, USA.|Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy.|Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, Canada.|Istituto ortopedico Gaetano Pini, Milano, Italy.|Universitas Airlangga Surabaya Indonesia, Surabaya, Indonesia.|Karolinska University Hospital, Stockholm, Sweden.|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.|University Medical Center Groningen, Groningen, Netherlands.|Rutgers New Jersey Medical School, Newark, New Jersey, USA.|RedSalud - Fundacion Arturo Lopez Perez, Santiago, Chile.|Sahlgren University Hospital, Gothenburg, Sweden.|University Hospital of Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|UCLA Department of Orthopaedic Surgery, Los Angeles, California, USA.|Moffitt Cancer Center, Tampa, Florida, USA.|Woodend Hospital Aberdeen, Aberdeen, UK.|Orthopaedic Oncology Unit, AOU Citta' della Salute e della Scienza, Torino, Italy.|Hospital del Nino Dr. Jose Esquivel, Panama, Panama.|Amsterdam University Medical Centre, Amsterdam, Netherlands.|Oxford Sarcoma Service, Oxford, UK.|Homo Bhabha Cancer Hospital & Reseacrh Centre, New Chandigarh, Tata Memorial Centre, New Chandigarh, India.|Leiden University Medical Center, Leiden, Netherlands.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Universitätsklinikum Münster Klinik für Allgemeine Orthopädie und Tumororthopädie, Münster, Germany.|Cleveland Clinic/Sarcoma Program, Cleveland, Ohio, USA.|Instituto Traumatologico Teodoro Gebauer/Clinica Alenama Universidad Del Desarrollo, Santiago, Chile.|Hospital Clinico Lozano Blesa, Zaragoza, Spain.|Hospital General Uniiversitario Gregorio Maranon, Madrid, Spain.|Ortopedia Oncologica e Ricostruttiva presso Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.|Instituto Nacional de Traumatologia e Ortopedia, Rio De Janeiro, Brazil.|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.|Hospital Oncológico Padre Machado, Caracas, Venezuela.|National Orthopaedic and Trauma Institute, Montevideo, Uruguay.|Centro Hospitalar Universitário de Coimbra, EP, Coimbra, Portugal.|Instituto Traumatologico Chile, Santiago, Chile.|Hospital Univ Clínico San Carlos, Madrid, Spain.|Musculoskeletal Infection Society, Salt Lake City, Utah, USA.|Virgen del Rocío University Hospital, Sevilla, Spain.|National University Hospital, Singapore, Singapore.|St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.|Department of Surgery, St Vincent's Hospital Melbourne, The University of Melbourne, Melbourne, Victoria, Australia.|Seoul St. Mary's Hospital/The Catholic University of Korea, Seoul, South Korea.|Pomeranian Medical University of Szczecin, Szczecin, Poland.|National Cancer Institute of Mexico, Mexico City, Mexico.|Mount Sinai Hospital MSK Oncology Unit, Toronto, Canada.|Hospital Metropolitano / Departamento de Ortopedia y Traumatología, Quito, Ecuador.|Pediatric Specialitis hospital / HEP, Caracas, Venezuela.|Robert Jones & Agnes Hunt, Oswestry, UK.|Hospital Universitario, Monterrey, Mexico.|Tel Aviv Medical Center, Tel Aviv, Israel.|University Hospital Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|Clinica Delgado, Lima, Peru.|Virgen de la Victoria - Málaga, Malaga, Spain.|Radboud University Medical Centre, Nijmegen, Netherlands.|Clínica Alemana, Santiago, Chile.|North Island Sarcoma Services, Auckland City Hospital, Auckland, New Zealand.|St. Vincents Hospital, Melbourne, Victoria, Australia.|Virginia Commonwealth University, Richmond, Virginia, USA.|IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.|Department of Orthopaedic Surgery and Traumatology, Ghent University Hospital, Ghent, Belgium.|Mediclinic Sandton, Johannesburg, South Africa.|University Hospital Coventry and Warwickshire, Coventry, UK.|Las Higueras Hosp, Concepcion, Chile.|Turku University Hospital, Turku, Finland.|Childrens Cancer Hospital, Cairo, Egypt.|Kyushu University, Fukuoka, Japan.|Acibadem Hospital Group, Complex Extremity Recon. Unit, Istanbul, Turkey.|Cliniques Universitaires Saint-Luc, CUSL, Brussels, Belgium.|Duke University, Durham, North Carolina, USA.|Infective Diseases Unit, Careggi University Hospital, Florence, Italy.|University of Porto, Porto, Portugal.|Dupuytren Teaching Hospital, Limoges, France.|Ortopedia y Traumatología HCVB, Pisa, Italy.|Centro Hospitalar Universitário de Coimbra, EPE, Coimbra, Portugal.|Sarcoma Service, LUKS University Hospital, Luzern, Switzerland.|Okayama University Hospital, Okayama, Japan.|Medical University of Vienna, Vienna, Austria.|Hospital Universitario Austral / Orthopedic Oncology Unit, Buenos Aires, Argentina.|Newcastle University, Newcastle, UK.|Hospital Marqués de Valdecilla, Cantabria, Spain.|Klinik Volmarstein, Volmarstein, Germany.|University of Maryland and McMaster University, Baltimore/Hamilton, USA/Canada.|Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.|Oxford University Hospital, Oxford, UK.|Insitut Universitaire du Cancer de Toulouse, Toulouse, France.|Instituto Nacional de Cancerología, Bogotá, Colombia.|Massachusetts General Hospital, Boston, Massachusetts, USA.|Hospital Del Ramon Y Madrid, Madrid, Spain.|Royal Infirmary Edinburgh, Edinburgh, UK.|Department of Orthopedic Surgery, Mayo Clinic, Phoenix, Arizona, USA.|First Department of Orthopaedic Surgery, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.|Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh, Tata Memorial centre, New Chandigarh, Punjab, India.|Glasgow Royal Infirmary, Glasgow, UK.|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.|Al Warith Cancer Institute, Baghdad, Iraq.|Department of tumor orthopedics, University of Essen, Essen, Germany.|Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria.|Memorial Sloan Kettering Cancer Center, New York, New York, USA.|Tec Salud, Monterrey, Mexico.|University of Alabama, Birmingham, Alabama, USA.|Groote Schuur Hospital, Cape Town, South Africa.|Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.|University of Miami, Miami, Florida, USA.|Fremantle Hospital, Fremantle, Western Australia, Australia.|National Orthopaedic Hospital, Lagos, Nigeria.|National Cancer Center Hospital Japan, Tokyo, Japan.|South Australian Bone & Soft Tissue Tumour Unit, Flinders Medical Centre, Adelaide, South Australia, Australia.|University of Liverpool, Liverpool, UK.|University of Bristol, Bristol, UK.|Department of Orthopaedic Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.|Orthopaedic Surgery, University Medical Center Groningen, Groningen, Netherlands.|North-Estonian Regional Hospital, Tallinn, Estonia.|Institut Jules Bordet, Brussels, Belgium.|Rehman Medical Institute and Medical College, Peshawar, Pakistan.|The University of Tokyo Hospital, Tokyo, Japan.|Barzelai Medical Center, Ashkelon, Israel.|University of Bonn, Bonn, Germany.|Johannesburg Hospital, Johannesburg, South Africa.|Clínica Universitaria de Navarra - Navarra, Navarra, Spain.|University Hospital of Tours, Tours, France.|Infant Jesus Teaching Hospital, Medical University of Warsaw, Warsaw, Poland.|Orthopedic University Hospital Heidelberg, Heidelberg, Germany.|Department of Radiology and Medical Imaging, Ghent University Hospital, Ghent, Belgium.|MD Anderson Cancer Center, Houston, Texas, USA.|The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, China.|Pontificia Universidad Javeriana, Bogota, Colombia.|Airlangga University, Surbaya, Indonesia.|Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.|Fundacion Hospital de Alcorcon, Madrid, Spain.|Hospital Necker, Gustave Roussy Institute, Paris, France.|Aphm Aix Marseille Université & Hôpital Européen Marseille, Marseille, France.|NHS Grampian, Aberdeen, UK.|Fundación CTIC Luis Carlos Sarmiento Angulo / Sarcoma Unit, Bogota, Colombia.|University of Iowa, Iowa City, Iowa, USA.|Kanazawa University, Kanazawa, Japan.|AUNA - The Americas / HPTU., Mendellin, Colombia.|Hospital Regional Universitario de Malaga, Malaga, Spain.|The Royal Children's Hospital Melbourne, Melbourne, Victoria, Australia.|Federal University of Parana, Curitiba, Parana, Brazil.|South Australian Bone & Soft Tissue Tumour Unit, Flinders Medical Centre, Adelaine, South Australia, Australia.|Keio University School of Medicine, Tokyo, Japan.|Orthopaedic Oncology Unit Penang General Hospital, George Town, Malaysia.|Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.|University of Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|Coxa Hospital for Joint Replacement, Tampere, Finland.|Cleveland Clinic, Cleveland, Ohio, USA.|St. Vincent's University Hospital Dublin, Dublin, Ireland.|Centro Hospitalar Universitário de Santo António, Porto, Portugal.|Vergelegen Mediclinic, Cape Town, South Africa.|Hannover Medical School, Hannover, Germany.|Hospital Universitario La Paz, Madrid, Spain.|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.|Istanbul Medeniyet University, Istanbul, Turkey.|University of Padova, Padova, Italy.|Miami Cancer Institute, Miami, Florida, USA.|Hospital Sant Pau, Barcelona, Spain.|Hospital Ramón Y Cajal, Madrid, Spain.|Doncaster and Bassetlaw NHS Trust, Doncaster, UK.|Rigshospitalet/University of Copenhagen/ Department of Orthopedics, Copenhagen, Denmark.|Evercare Hospital, Lahore, Pakistan.|Cancer Institute (WIA), Chennai, India.|Ganga Medical Centre & Hospitals, Coimbatore, India.|Lahey Clinic, Burlington, Massachusetts, USA.|University of California, Davis, Sacramento, California, USA.|Newcastle University, Newcastle Upon Tyne, UK.|Hospital of Traumatology and Orthopaedic Latvia, Riga, Latvia.|Rennes University Hospital, Rennes, France.|Clinica Sebastian De Belalcazar Cali Colombia, Cali, Colombia.|Walsall Healthcare NHS Trust, Walsall, UK.|IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, Italy.|Department of Orthopedics Oncology and Reconstructive Surgery, University Hospital Careggi, Florence, Italy.|Cliniques Universitaires Saint-Luc, Brussels, Belgium.|Orthopaedic Oncology, Careggi University Hospital, Florence, Italy.|Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, UK.|King Hussein Cancer Center/Orthopedic Unit, Amman, Jordan.|Saleem Memorial Hospital, Lahore, Pakistan.|Michigan Medicine / University of Michigan, Ann Arbor, Michigan, USA.|Inot oncólogy orthopaedic, Montevideo, Uruguay.|University Hospitals Leuven, Leuven, Belgium.|Johannesburg Surgical Hospital, Johannesburg, South Africa.|The Wesley Hospital, Auchenflower, Queensland, Australia.|Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh, Tata Memorial Centre, New Chandigarh Punjab, India.|University of Florida, Gainesville, Florida, USA.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.|First Department of Orthopaedic Surgery 'ATTIKON' University General Hospital, Athens, Greece.|Princess Alexandra Hospital, Brisbane, Australia.|The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.|Department of Paediatric Haematology-Oncology AOU ""Anna Meyer"" IRCCS, Florence, Italy.|Medical and Health Services, Vestreviken Hospital Trust, Division of Orthopaedic Oncology, Oslo University Hospital, Oslo, Norway.|Mayo Clinic Orthopedics, Phoenix, Arizona, USA.|Department of Orthopaedics, Tartu University Hospital, University of Tartu, Tartu, Estonia.|Hospital Sant Joan de Deu, Barcelona, Spain.|University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.|Tamepere University Hospital, Tampere, Finland.|Hospital Univ. Virgen de la Arrixaca, Murcia, Spain.|Centro Oncológico Antioquia, Antioquia, Colombia.|UZA Orthopaedic Oncology and Traumatology, Antwerp, Belgium.|Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.|Centre Léon Berard, Lyon, France.|Hospital Universitari Vall D'Hebrón - Barcelona, Barcelona, Spain.|Amsterdam University Medical Centers, Amsterdam, Netherlands.|Department of Radiology and Medical Imaging, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.|Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine.|Leuven University Hospitals, Leuven, Belgium.|University Hospital Cologne, Cologne, Germany.|Universiti Sains Malaysia, Penang, Malaysia.|University of the Philippines, Philippine General Hospital, Manila, Philippines.|University Hospital Jena, Jena, Germany.|Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.|Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.|Department of Orthopaedics, University Medical Center Groningen, Groningen, Netherlands.|Singapore General Hospital, Singapore, Singapore.|Pontificia Universidad Católica de Chile, Santiago, Chile.|McMaster University - Juravinski Cancer Centre, Hamilton, Canada.","Khan Z, Khan Z A, Zamorra T, Gulia A, Lozano-Calderon S A, Kurisunkal V J, Jeys L M, Laitinen M K, Abad Repiso S, Abdelbary H, Abiad Mejia A, Abood A A, Abou-Nouar G, Abril Martin J C, Abu Elhamd A, Zumarraga J P, et al.",https://pubmed.ncbi.nlm.nih.gov/41260234/,"The study found significant global inconsistencies in the use of debridement, antibiotics, and implant retention (DAIR) for treating periprosthetic joint infections in orthopaedic oncology. Surgeons varied in their surgical approaches, with only 39% exchanging all modular components during DAIR. The study proposes standardized definitions for DAIR procedures to improve consistency in treatment and patient outcomes."
40997291,Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.,No abstract available.,J Clin Oncol,"Nov 20, 2025",2025,Nov,20,Vile R G,Vile R G,"Departments of Molecular Medicine and Immunology, Mayo Clinic, Rochester, MN.|Joan Reece Professor of Immuno-Oncology, Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom.|King's College, London, United Kingdom.",Vile R G,https://pubmed.ncbi.nlm.nih.gov/40997291/,"This research likely explores combining two different cancer treatments: oncolytic virotherapy, which uses viruses to kill cancer cells, and cancer immunotherapy, which boosts the body's immune system to fight cancer. The goal is to find a way to treat melanoma, a type of skin cancer, that has become resistant to other treatments."
41258662,Prevalence of Malignancy Among Incidental Indeterminate Adrenal Nodules on Contrast-Enhanced CT in Patients Without Known Cancer: A Multiinstitutional Study.,"Background: Adrenal incidentalomas are common findings at contrast-enhanced CT, yet their management remains controversial. Objective: The purpose of this study was to determine the prevalence of malignancy among incidental indeterminate adrenal nodules detected on contrast-enhanced CT in patients without known cancer. Methods: We performed a 12-institution retrospective cohort study of adult patients without known cancer who underwent contrast-enhanced CT of the abdomen from January 1, 2010, to April 2, 2016. Consecutive reports from 10,646 cases were reviewed. CT images were reviewed for 2603 cases with reports describing an adrenal nodule measuring 1 cm or larger. Malignancy or benignity was determined using the following reference standards: pathology, diagnostic imaging (attenuation on unenhanced CT < 10 HU or signal-intensity loss at chemical shift MRI), imaging stability for at least 1 year, or clinical follow-up of at least 5 years. Descriptive statistics were performed using the binomial exact method and chi-square test. Results: The final cohort included 1320 patients (813 women, 507 men; mean age, 63.1 ± 15.2 years) with 1506 adrenal nodules. Mean nodule size was 2.1 cm ± 0.7 cm (range, 1.0-10.7 cm; IQR, 1.6-2.5 cm). The prevalence of malignancy among all nodules, nodules measuring 1-2 cm, nodules measuring 2-4 cm, and nodules measuring more than 4 cm was 0.07% (1/1506; 95% CI, 0.0-0.37%), 0.0% (0/773; 95% CI, 0.0-0.39%), 0.14% (1/694; 95% CI, 0.0-0.80%), and 0.0% (0/39; 95% CI, 0.0-7.4%). respectively. The one malignant nodule was an adrenocortical carcinoma diagnosed 9 years after initial detection. A total of 940 nodules underwent unenhanced CT after the index CT; all were benign. Of these, 654 were less than 10 HU, 157 were 10-20 HU, and 129 were more than 20 HU. Conclusion: The prevalence of malignancy among incidental indeterminate adrenal nodules on contrast-enhanced CT in patients without known cancer was exceedingly low. Clinical Impact: Follow-up imaging is not warranted for small (1-2 cm) incidental indeterminate adrenal nodules detected on contrast-enhanced CT in patients without known cancer.",AJR. American journal of roentgenology,"Nov 19, 2025",2025,Nov,19,Corwin M T|Getz M L D|Branson C M|Aljahdali S H|Anand R|Blake M A|Brook O R|Caoili E M|Challapalli J|Chung R|Dang T|Elsayes K M|Glazer D I|Kim J|Koshy R M|Lee J T|Mashar M|Mayo-Smith W W|McPhedran R L|Navin P J|Nisiewicz M J|Petrocelli R|Schieda N|Solimanie S|Song J H|Sotman T E|Summerlin D S|Taffel M T|Tu W|Zahid M|Remer E M,McPhedran R L|Navin P J,"Department of Radiology, University of California, Davis Medical Center, Sacramento, CA.|University of Ottawa, Department of Radiology Ottawa, ON, CA.|Beth Israel Deaconess Medical Center, Department of Radiology, Boston, MA.|Massachusetts General Hospital, Department of Radiology, Boston, MA.|University of Michigan, Department of Radiology, Ann Arbor, MI.|Brown University Health, Department of Radiology, Providence, RI.|Cleveland Clinic, Imaging Institute and Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH.|University of Texas MD Anderson Cancer Center, Department of Diagnostic Imaging, Houston, TX.|Brigham and Women's Hospital, Department of Radiology, Boston, MA.|Harvard Medical School, Boston, MA.|NYU Langone Health, Department of Radiology, New York, NY.|University of Alberta, Canada, Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada.|University of Kentucky, Department of Radiology, Lexington, KY.|Mayo Clinic Rochester, Department of Radiology, Rochester, MN.|University of Alabama at Birmingham, Department of Radiology, Birmingham, AL.","Corwin M T, Getz M L D, Branson C M, Aljahdali S H, Anand R, Blake M A, Brook O R, Caoili E M, Challapalli J, Chung R, Dang T, Elsayes K M, Glazer D I, Kim J, Koshy R M, Remer E M, et al.",https://pubmed.ncbi.nlm.nih.gov/41258662/,"This study found that the prevalence of malignancy among incidental indeterminate adrenal nodules detected on contrast-enhanced CT in patients without known cancer is very low, less than 0.1%. The findings suggest that follow-up imaging is not necessary for small (1-2 cm) incidental adrenal nodules in these patients, which could reduce unnecessary medical tests and costs."
41253179,Prospective clinical trial analyzing serum mast cell tryptase levels and arthrofibrosis rates after total knee arthroplasty.,"Arthrofibrosis affects a notable percentage of patients after total knee arthroplasty (TKA). Elevated serum mast cell tryptase (SMCT) levels have been linked to fibrosis, suggesting that SMCT could serve as a biomarker for arthrofibrosis. As such, the aims of this study were to assess SMCT levels in TKA patients, and their possible association with arthrofibrosis and clinical outcomes in a prospective clinical trial.We conducted a prospective study involving 219 patients undergoing primary TKA at a single academic medical centre between January 2018 and December 2022. SMCT levels were measured preoperatively, immediately postoperatively, and at six weeks, three months, and one year postoperatively. Secondary outcomes included revision rates, complications, and Knee Society Scores (KSSs). Allergic and inflammatory conditions were assessed for their influence on SMCT levels.At one year postoperatively, eight patients had developed arthrofibrosis (4%), and three (1.5%) had undergone manipulation under anaesthesia. The mean preoperative SMCT level was 5.6 µg/L (SD 3.4), which decreased significantly to 4.1 µg/L (SD 2.7) immediately postoperatively (p < 0.001). At six weeks the mean SMCT level was 6.4 µg/l (SD 4.1), and was 6.1 µg/l at both three months (SD 4.1) and one year (SD 4.0). Elevated preoperative SMCT levels were not significantly associated with the risk of arthrofibrosis development (OR 3; p = 0.370), nor were immediate postoperative levels (OR 2; p = 0.754) or those at six weeks (OR 1; p = 0.989). Of note, elevated SMCT levels at three months (OR 5; 95% CI 0.4 to 64; p = 0.191) and one year (OR 13; 95% CI 1 to 232; p = 0.077) trended toward an increased risk of arthrofibrosis development, without reaching significance.In patients undergoing TKA, with the numbers included in this study, there was no significant difference in SMCT levels between patients who did and did not develop arthrofibrosis at any timepoint. However, there was a trend towards elevated SMCT levels at three months and one year in those who developed arthrofibrosis, which merits further study.© 2025 Meissner et al.",Bone & joint research,"Nov 19, 2025",2025,Nov,19,Meissner N|Tibbo M E|Larson D R|Morrey M E|Sanchez-Sotelo J|Hannon C P|Berry D J|Abdel M P,Meissner N|Tibbo M E|Larson D R|Morrey M E|Sanchez-Sotelo J|Hannon C P|Berry D J|Abdel M P,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA.","Meissner N, Tibbo M E, Larson D R, Morrey M E, Sanchez-Sotelo J, Hannon C P, Berry D J, Abdel M P",https://pubmed.ncbi.nlm.nih.gov/41253179/,"This study examined the relationship between serum mast cell tryptase (SMCT) levels and the development of arthrofibrosis (stiffening of the knee joint) after total knee replacement surgery. The researchers found that while SMCT levels did not significantly predict arthrofibrosis, there was a trend towards higher SMCT levels at 3 months and 1 year in patients who developed the condition. This suggests that SMCT may have potential as"
41254255,Diagnostic performance of X-ray-based deep learning models for detecting ankle and foot fractures: a systematic review and meta-analysis.,"Lower extremity fractures are prevalent in vulnerable populations leading to significant burdens, which highlight the need for timely and precise diagnosis. Integrating deep learning with imaging findings has shown promising results for enhancing fracture detection accuracy. This study assesses the diagnostic accuracy of AI models using X-ray images to detect ankle and foot fractures and investigates the probable factors influencing their performance.A comprehensive search of four databases was done up to September 30th, 2025. Studies that investigated the accuracy of deep learning models for the detection of ankle and foot fractures utilizing X-rays were included. A bivariate random-effects model was used to perform meta-analysis.A total of 506 studies were reviewed, and 14 were included in the meta-analysis. Analysis of all the representative models of the included studies had a cumulative sensitivity and specificity of 93.2% and 94.5% (95% CI 88.8-95.9%, 90.1-97.0%, respectively, I2 6.6%). The pooled F1 score was estimated at 0.94 (95% CI 0.88-0.97). Subgroup analysis revealed no difference in the sensitivity or specificity of studies using multi-view vs. single-view X-rays (P = 0.64, P = 0.89, respectively). Models detecting calcaneal fractures performed significantly better than models detecting foot or ankle fractures, with a pooled sensitivity of 95.1% (95% CI 93.0-96.6%, P = 0.008), specificity of 98.3% (95% CI 97.00-99.0%), and a DOR of 1751.8 (95% CI 445.9-6882.5). The type of dataset used (validation vs. test, internal testing vs. external testing) did not significantly affect performance.Deep learning models can be considered a notably accurate method for the detection of ankle and foot fractures. Further studies with larger samples, external validation, and clinical implementations are required.This systematic review and meta-analysis study was registered with PROSPERO, registration number CRD42024624044.© 2025. The Author(s), under exclusive licence to International Skeletal Society (ISS).",Skeletal radiology,"Nov 19, 2025",2025,Nov,19,Pahlevan-Fallahy M|Hosseinzadeh N|Shaker F|Asgari A|Teymouri Athar M M|Rouzrokh P,Rouzrokh P,"School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.|School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. drasgari1@yahoo.com.|School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.|Department of Radiology & Biomedical Imaging, Yale School of Medicine, Yale University, New Haven, CT, USA.|Department of Radiology, Mayo Clinic Artificial Intelligence Laboratory, Mayo Clinic, Rochester, MN, USA.","Pahlevan-Fallahy M, Hosseinzadeh N, Shaker F, Asgari A, Teymouri Athar M M, Rouzrokh P",https://pubmed.ncbi.nlm.nih.gov/41254255/,"Deep learning models using X-ray images can accurately detect ankle and foot fractures, with a sensitivity and specificity of over 90%. These AI-based tools could potentially improve the timely and precise diagnosis of lower extremity fractures, which are common in vulnerable populations."
41257358,Pediatric Dermatology Learning Needs Identified Through Continuing Certification Program Assessments of the American Board of Dermatology.,"The American Board of Dermatology (ABD) Continuing Certification Program (CCP) for board-certified dermatologists helps advance its vision, which includes quarterly web-based knowledge assessments. In 2022, the ABD began a review of gaps in knowledge assessment, practice improvement reporting, and areas of educational interest. The American Board of Medical Specialties directed member boards to share frequently occurring deficits with specialty societies to identify and prioritize gaps. This report summarizes pediatric dermatology findings from this review.© 2025 Wiley Periodicals LLC.",Pediatric dermatology,"Nov 19, 2025",2025,Nov,19,Stratman E J|Schaffer J V|Miller S J|Bruckner A L|Gonzalez M E|Zaenglein A L|Roenigk R K,Roenigk R K,"Department of Dermatology, Marshfield Clinic Health System, Marshfield, Wisconsin, USA.|American Board of Dermatology, Newton, Massachusetts, USA.|Hackensack Meridian Health, Paramus, New Jersey, USA.|Pediatric Dermatology, Children's Hospital Colorado, Aurora, Colorado, USA.|Pediatric Dermatology, University of Miami Health System, Miami, Florida, USA.|Department of Dermatology and Pediatric Dermatology, Penn State Health, Hershey, Pennsylvania, USA.|Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.","Stratman E J, Schaffer J V, Miller S J, Bruckner A L, Gonzalez M E, Zaenglein A L, Roenigk R K",https://pubmed.ncbi.nlm.nih.gov/41257358/,The study found that board-certified dermatologists have knowledge gaps in pediatric dermatology. This information will help the American Board of Dermatology and specialty societies develop targeted educational programs to improve the care of children with skin conditions.
41258098,Spatial multi-omics identifies aggressive prostate cancer signatures highlighting pro-inflammatory chemokine activity in the tumor microenvironment.,"Understanding the characteristics of the tumor microenvironment (TME) associated with aggressive prostate cancer (PCa) is essential for accurate diagnosis and treatment. We interrogated spatially resolved multi-omics data to find molecular stratifiers of aggressive PCa. We report an aggressive prostate cancer (APC) gene expression signature predictive of increased risk of relapse and metastasis in a cohort of 1,588 patients. Further, we present a chemokine-enriched-gland (CEG) signature specific to non-cancerous prostatic glands from patients with aggressive cancer. The CEG signature is characterized by upregulated expression of pro-inflammatory chemokines, club-like cell enrichment, and immune cell infiltration of surrounding stroma. The activity of both signatures is correlated with reduced citrate and zinc levels and loss of normal prostate secretory gland functions. In summary we report that an increased inflammatory status linked to chemokine production, club-like cell enrichment, and metabolic changes in normal-appearing prostatic glands is associated with the subsequent development of aggressive PCa.© 2025. The Author(s).",Nature communications,"Nov 19, 2025",2025,Nov,19,Krossa S|Andersen M K|Sandholm E M|Wess M|Kiviaho A|Sharma A|Hakkola S|Hao Y|Alshalalfa M|Davicioni E|Viset T|Størkersen Ø|Karnes R J|Spratt D E|Giskeødegård G F|Nykter M|Rye M B|Urbanucci A|Tessem M,Karnes R J,"Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. sebastian.krossa@ntnu.no.|Central Staff, St. Olavs Hospital HF, Trondheim, Norway. sebastian.krossa@ntnu.no.|Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway.|Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.|Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and TAYS Cancer Center, Tampere, Finland.|HUNT Center for Molecular and Clinical Epidemiology, Department of Public Health and Nursing, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.|Veracyte, San Diego, CA, USA.|Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.|Department of Urology, Mayo Clinic, Rochester, MN, USA.|UH Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.|Foundation for the Finnish Cancer Institute, Helsinki, Finland.|Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.|Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.|Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway. may-britt.tessem@ntnu.no.|Clinic of Surgery, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. may-britt.tessem@ntnu.no.","Krossa S, Andersen M K, Sandholm E M, Wess M, Kiviaho A, Sharma A, Hakkola S, Hao Y, Alshalalfa M, Davicioni E, Viset T, Størkersen Ø, Karnes R J, Spratt D E, Giskeødegård G F, Tessem M, et al.",https://pubmed.ncbi.nlm.nih.gov/41258098/,"The key finding of this research is the identification of an aggressive prostate cancer (APC) gene expression signature that can predict increased risk of relapse and metastasis. Additionally, the researchers found a chemokine-enriched-gland (CEG) signature in non-cancerous prostatic glands of patients with aggressive cancer, characterized by increased pro-inflammatory chemokines, club-like cell enrichment, and immune cell infiltration. This suggests that an inflammatory state in"
41258275,Outcomes of left atrial appendage occlusion with atrial fibrillation ablation: a real-world analysis from the National Inpatient Sample database.,"The safety and cost of concomitant atrial fibrillation (AF) ablation and left atrial appendage occlusion (LAAO) procedure remain unknown.The study sought to determine real-world outcomes of AF patients who underwent LAAO with ablation.The National Inpatient Sample and International Classification of Diseases-Tenth Revision codes were used to identify patients who underwent LAAO with and without AF ablation during the years 2016-2022. The outcomes assessed included procedural complications and resource utilization.LAAO with AF ablation was associated with a higher rate of overall (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.37-1.74), major complications (OR 1.38, 95% CI 1.18-1.60), non-home discharge (OR 1.55, 95% CI 1.23-1.96), prolonged length of stay > 1 day (OR 3.21, 95% CI 2.92-3.52), and increased hospitalization costs as defined by median cost > $25,926 (OR 19.42, 95% CI 16.21-23.25) when compared to LAAO alone after adjustment for potential confounding variables. Patients who underwent LAAO with ablation were also more likely to receive pacemaker implantation (3.6% vs 0.2%, P < 0.001) and experience acute kidney injury (3.9% vs 2.1%, P < 0.001) and non-ST elevation myocardial infarction (3.7% vs 1.5%, P < 0.001).In a large, contemporary, real-world study of LAAO procedures in the USA, concomitant AF ablation was associated with a higher rate of overall and major complications and an increased resource utilization.© 2025. The Author(s).",J Interv Card Electrophysiol,"Nov 19, 2025",2025,Nov,19,Khan M Z|Devera J L|Alruwaili W|Naveed M A|Hakim Y M|Leon W E|Nguyen A|Agarwal S|Asad Z U A|Khan S|Gonuguntla K|Ice D|Munir M B,Agarwal S,"Division of Cardiology, Deborah Heart and Lung Center, Brown Mills, NJ, USA.|Division of Cardiovascular Medicine, Section of Cardiac Electrophysiology, University of California Davis School of Medicine, 4860 Y St. Suite 2800, Sacramento, CA, 95817, USA.|Department of Medicine, West Virginia University, Morgantown, WV, USA.|Department of Cardiology, Dow Medical College, Karachi, Pakistan.|Department of Cardiology, Mayo Clinic, Rochester, MN, USA.|Division of Cardiology, University of Oklahoma, Oklahoma City, OK, USA.|Department of Medicine, Khyber Medical University, Peshawar, Pakistan.|Division of Cardiology, Hartford Hospital Heart and Vascular Institute, Norwich, CT, USA.|Division of Cardiovascular Medicine, Section of Cardiac Electrophysiology, University of California Davis School of Medicine, 4860 Y St. Suite 2800, Sacramento, CA, 95817, USA. mbmunir@ucdavis.edu.","Khan M Z, Devera J L, Alruwaili W, Naveed M A, Hakim Y M, Leon W E, Nguyen A, Agarwal S, Asad Z U A, Khan S, Gonuguntla K, Ice D, Munir M B",https://pubmed.ncbi.nlm.nih.gov/41258275/,"This study found that performing left atrial appendage occlusion (LAAO) along with atrial fibrillation (AF) ablation was associated with a higher risk of complications and increased healthcare costs compared to LAAO alone. Patients who underwent the combined procedure had more overall and major complications, were more likely to be discharged to a non-home facility, and had longer hospital stays and higher hospitalization costs."
41258631,"Avascular necrosis in antiphospholipid syndrome: pathophysiology, risk factors, and management.","Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in the presence of antiphospholipid antibodies, which include lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I. The updated 2023 ACR/EULAR classification criteria recognize microvascular features of APS but not orthopedic complications. Among these, avascular necrosis (AVN) is an uncommon and underrecognized manifestation, characterized by ischemic death of bone tissue, most often affecting the femoral head, knee, talus, and humeral head. The link between APS and AVN remains unclear and warrants further review.To explore the association between APS and AVN, focusing on its pathophysiology, prevalence, risk factors, clinical presentation, and management strategies.A comprehensive search was performed across medical databases, including PubMed, Medline, and Google Scholar, using relevant keywords.AVN is a rare but significant complication of APS, with prevalence ranging from 0.9 to 20%, depending on the study design and population analyzed. The pathogenesis is primarily attributed to microvascular thrombosis and hypercoagulability caused by antiphospholipid antibodies. Identified risk factors include prolonged glucocorticoid use, thrombocytopenia, pregnancy, and underlying microvascular abnormalities. Early detection via MRI and timely interventions, such as anticoagulation therapy, lifestyle modifications, and surgical procedures, improve patient outcomes and prevent disease progression.Understanding the multifaceted nature of AVN in APS is crucial for timely diagnosis and effective management. Further research is needed to establish clear preventative strategies and optimize long-term treatment protocols, ultimately improving patient care and clinical outcomes.© 2025. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).",Clinical rheumatology,"Nov 19, 2025",2025,Nov,19,Zankar R|Jamal R E|Hasbani G E|Uthman I,Hasbani G E,"Faculty of Medicine, American University of Beirut, Beirut, Lebanon.|Division of Rheumatology, Mayo Clinic, Rochester, MN, USA.|Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon. iuthman@aub.edu.lb.","Zankar R, Jamal R E, Hasbani G E, Uthman I",https://pubmed.ncbi.nlm.nih.gov/41258631/,"Avascular necrosis (AVN) is a rare but serious complication of antiphospholipid syndrome (APS), an autoimmune disorder. The main cause of AVN in APS is believed to be microvascular blood clots and increased blood clotting. Early detection through MRI and prompt treatment, including anticoagulation therapy and lifestyle changes, can help prevent disease progression and improve patient outcomes."
41258731,Long-term Outcomes of Long Head of the Triceps Transfer in Patients With Amyoplasia.,"Achieving active elbow flexion in children with amyoplasia can greatly improve independence in activities of daily living. This study investigated long-term outcomes of the long head triceps transfer procedure performed for that purpose.A retrospective review of medical records was performed for all patients with amyoplasia who underwent a long head triceps transfer between January 1, 2008 and December 31, 2019. Patients with follow-up of less than 2 years were excluded. Pre- and postoperative range of motion were recorded, and patient-reported outcome measures included a visual analog scale (VAS) for function (scale 0 to 10), a VAS for overall satisfaction (scale 0 to 10), and the Pediatric Outcomes Data Collection Instrument (PODCI). Pre- and postoperative motion were compared via paired t tests.Seventeen patients (25 extremities) were included. Postoperatively, average active elbow flexion was 78 degrees against gravity and 90 degrees with gravity eliminated. Patients with active elevation of the shoulder ≥90 degrees showed average active elbow flexion with gravity eliminated of 85 degrees. The mean VAS score for improvement of function was 8.3 (range, 4 to 10) from parents and 9.0 (range, 8 to 10) from patients older than 10 years. The mean VAS scores for overall satisfaction were 8.0 (range, 5 to 10) and 8.1 (range, 6 to 10), respectively. Mean PODCI scores ranged from 63 to 73 for upper extremity, 83 to 76 for transfer and basic mobility, 64 to 73 for sports participation, 83 to 95 for pain and comfort, 90 to 97 for happiness, and 74 to 79 for global function.The long head of the triceps transfer is an effective treatment modality for patients with amyoplasia who present with absent active elbow flexion, good passive elbow flexion, and well-defined long head and lateral heads of the triceps muscle. Overall, patients gained an active range of elbow motion with no significant functional elbow contracture and improved quality of life. However, patients with a history of elbow release surgery are at higher risk of flexion contracture and should be screened especially carefully.Level IV-case series.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Journal of pediatric orthopedics,"Nov 19, 2025",2025,Nov,19,Reghunathan M|Weber A D|Schneidau C|Beckwith T|Oishi S,Reghunathan M,"Division of Hand Surgery, Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.|Department of Pediatric Orthopedics, University Children's Hospital, Balgrist University Hospital, Zürich.|Center for Excellence in Hand and Upper Extremity Surgery, Scottish Rite for Children, Dallas, TX.","Reghunathan M, Weber A D, Schneidau C, Beckwith T, Oishi S",https://pubmed.ncbi.nlm.nih.gov/41258731/,"The study found that the long head triceps transfer procedure can significantly improve active elbow flexion and overall function in children with amyoplasia, a type of congenital limb deformity. Patients reported high satisfaction and improved quality of life after the surgery, though those with prior elbow release surgery may be at higher risk of complications."
41259008,Enough to Promote Changes to Current Management of Catatonia?,No abstract available.,JAMA psychiatry,"Nov 19, 2025",2025,Nov,19,Penaluna B K|Morgan R J|Allen N D,Penaluna B K|Morgan R J|Allen N D,"Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota.","Penaluna B K, Morgan R J, Allen N D",https://pubmed.ncbi.nlm.nih.gov/41259008/,"This research likely explores whether the current management or treatment of catatonia, a mental health condition, is sufficient or needs to be changed. The study may investigate the effectiveness of the current approaches to managing catatonia and whether there is a need for improvements or new strategies in the treatment of this condition."
41259271,Neurodevelopmental effects of genetic frontotemporal dementia mutations revealed by total intracranial volume differences.,"BackgroundConverging evidence hints at neurodevelopmental effects in people at risk of genetic frontotemporal dementia (FTD).ObjectiveWe investigated total intracranial volume (TIV), a neuroimaging marker of neurodevelopment, and years of education differences between adult mutation carriers and familial non-mutation carriers, as measures of the structural and functional neurodevelopmental effects of FTD-causing genetic mutations.MethodsThis cross-sectional cohort study, facilitated through the FTD Prevention Initiative (FPI), included 902 adult pathogenic mutation carriers of GRN, MAPT, or C9orf72, and 532 familial non-carriers. ANCOVAs were computed to compare TIV and education between groups per gene. Pearson's correlations were used to examine associations between TIV and education.ResultsMutation carriers (mean ± SD age = 50.0 ± 13.2 years, sex = 55% female, n(GRN) = 298, n(MAPT) = 187, n(C9orf72) = 417) were compared to familial non-carriers (age = 48.0 ± 12.9 years, sex = 58% female, n(GRN) = 201, n(MAPT) = 114), n(C9orf72) = 217). Consistent with prior findings in young adults, GRN carriers showed larger TIV, on average by 20531 mm3, compared to familial non-carriers (95% CI [85.4, 40977], p = 0.049, η2p = 0.008). Larger TIV correlated with higher years of education in GRN carriers (95% CI [0.01, 0.24], r(295) = 0.12, p = 0.03) and GRN non-carriers (95% CI [0.08, 0.34], r(198) = 0.21, p = 0.002). MAPT carriers demonstrated smaller TIV than non-carriers, on average by 29896 mm3 (95% CI [-58248, -1545], p = 0.039, η2p = 0.02). Models with C9orf72 and education as outcome variables did not reveal significant differences.ConclusionsIn support of the neurodevelopmental hypothesis of FTD, GRN and MAPT mutations are linked to structural neurodevelopmental changes in TIV. Further research is needed to identify mechanisms underlying neurodevelopmental influences of FTD mutations and ascertain their suitability as intervention targets.",Journal of Alzheimer's disease : JAD,"Nov 19, 2025",2025,Nov,19,So I|Bouzigues A|Russell L L|Foster P H|Ferry-Bolder E|van Swieten J C|Jiskoot L C|Seelaar H|Sanchez-Valle R|Laforce R|Graff C|Galimberti D|Vandenberghe R|de Mendonça A|Tiraboschi P|Santana I|Gerhard A|Levin J|Sorbi S|Otto M|Pasquier F|Ducharme S|Butler C R|Le Ber I|Tartaglia M C|Masellis M|Rowe J B|Synofzik M|Moreno F|Borroni B|Kolander T|Mester C|Brushaber D|Kantarci K|Heuer H W|Forsberg L K|Rohrer J D|Boeve B F|Boxer A L|Rosen H J|Finger E C,Kolander T|Mester C|Brushaber D|Kantarci K|Forsberg L K|Boeve B F,"Neuroscience, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.|Lawson Health Research Institute, Parkwood Institute, London, ON, Canada.|Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.|Department of Neurology and Alzheimer Centre, Erasmus MC University Medical Centre, Rotterdam, the Netherlands.|Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.|Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Québec City, QC, Canada.|Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Bioclinicum, Karolinska Institutet, Stockholm, Sweden.|Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.|University of Milan, Milan, Italy.|Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium.|Faculty of Medicine, University of Lisbon, Lisbon, Portugal.|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.|University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.|Division of Psychology Communication and Human Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.|Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.|Department of Neuropharmacology, University of Florence, Florence, Italy.|Department of Neurology, University of Ulm, Ulm, Germany.|University of Lille, Lille, France.|Douglas Mental Health University Health Centre, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.|Global Brain Health, Department of Brain Sciences, Imperial College London, London, UK.|Sorbonne Université, Paris Brain Institute - Institut du Cerveau - ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France.|Tanz Centre for Research in Neurodegenerative Diseases, Division of Neurology, University of Toronto, Toronto, ON, Canada.|Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre; Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.|Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.|Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.|Cognitive Disorders Unit, Department of Neurology, Hospital Universitario Donostia, San Sebastian, Spain.|Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.|Department of Neurology, Mayo Clinic, Rochester, MN, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Division of Neuroradiology, Mayo Clinic, Rochester, MN, USA.|Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.|Department of Clinical Neurological Sciences, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.","So I, Bouzigues A, Russell L L, Foster P H, Ferry-Bolder E, van Swieten J C, Jiskoot L C, Seelaar H, Sanchez-Valle R, Laforce R, Graff C, Galimberti D, Vandenberghe R, de Mendonça A, Tiraboschi P, Finger E C, et al.",https://pubmed.ncbi.nlm.nih.gov/41259271/,"This study found that people with genetic mutations linked to frontotemporal dementia (FTD) show differences in total intracranial volume, a measure of brain development, compared to their unaffected family members. Specifically, people with GRN mutations had larger brains, while those with MAPT mutations had smaller brains. These findings suggest that the genetic causes of FTD may have effects on brain development, which could be important for understanding and potentially treating the"
41259653,A framework for using DNA methylation-based modelling for the clinical management of cranial meningioma.,"DNA methylation profiling can be used to robustly predict postsurgical outcomes and response to radiotherapy (RT) for meningioma patients. To allow for seamless integration of these complementary models into clinical practice, a practical framework is needed.We leveraged a cohort of nearly 2000 surgically-treated meningiomas with DNA methylation profiling and clinical outcomes data. Existing methylation-based prediction models were dichotomized to yield four risk groups: low and high recurrent risk, each with RT sensitive and resistant subgroups. Risk groups were correlated with progression-free survival in the context of existing biomarkers including extent of resection and WHO grade.We first demonstrated that all risk groups benefit from gross total resection. All ""high-risk, RT sensitive"" tumors (n = 306, 15.7%) also benefited from adjuvant RT: after GTR, median PFS increased from 4.68 (4.13-9.48) years to not reached (p = 0.003); after STR, from 2.12 (1.59-3.02) to 4.09 (3.41-not reached) years (p = 0.004). ""Low-risk, RT sensitive cases"" (n = 1207, 61.8%) also benefitted from RT after STR (median PFS 7.39 (6.66-12.8) vs. 16.53 (10.35-not reached) years, p = 0.03), suggesting that RT be considered in these patients. Neither ""low-risk RT resistant"" (n = 84, 4.3%) nor ""high-risk RT resistant"" (n = 356, 18.2%) cases benefitted from RT, and the latter group was associated with universally poor outcomes.We identify methylation-defined risk groups of meningioma for which additional benefit is gained from adjuvant RT, leading to a clinical decision-making framework for straightforward integration of molecular models into clinical practice.© The Author(s) 2025. PPublished by Oxford University Press on behalf of the Society for Neuro-Oncology.",Neuro-oncology,"Nov 19, 2025",2025,Nov,19,Landry A P|Wang J Z|Patil V|Ajisebutu A|Gui C|Yefet L S|Ellenbogen Y|Liu J|Mamatjan Y|Wei Q|Singh O|Mansouri S|Ehret F|Capper D|Cohen-Gadol A A|Tabatabai G|Tatagiba M|Behling F|Barnholtz-Sloan J S|Sloan A E|Chambless L B|Mansouri A|Makarenko S|Yip S|Tsang D S|Gao A|Aldape K|Nassiri F|Zadeh G,Zadeh G,"MacFeeters Hamilton Neuro-Oncology Program, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, ON, Canada.|Division of Neurosurgery, Department of Surgery, University of Toronto, Toronto, ON, Canada.|Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.|Department of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.|German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité - Universitätsmedizin Berlin, Germany.|Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.|Dept of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, CA.|German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.|Cluster of Excellence (EXC 2180) ""Image Guided and Functionally Instructed Tumor Therapies"", Eberhard Karls University Tübingen, Tübingen, Germany.|Department of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, Comprehensive Cancer Center, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.|Department of Neurosurgery, Center for Neuro-Oncology, Comprehensive Cancer Center, Eberhard Karls University Tübingen, Tübingen, Germany.|Central Brain Tumor Registry of the United States, Hinsdale, IL, United States.|Trans Divisional Research Program (TDRP), Division of Cancer Epidemiology and Genetics (DCEG), National Cancer Institute, Bethesda, MD, United States.|Center for Biomedical Informatics & Information Technology (CBIIT), National Cancer Institute, Bethesda, MD, United States.|Department of Neurological Surgery & Piedmont, Brain Tumor Center, Atlanta, GA, 30309.|Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, United States.|Department of Neurosurgery, Penn State Milton S. Hershey Medical Center, Hershey, PA, US.|Division of Neurosurgery, University of British Columbia, Vancouver, BC, Canada.|Department of Pathology & Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.|Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada.|Division of Laboratory Medicine and Pathobiology, University Health Network, Toronto, ON, Canada.|Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.|Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.","Landry A P, Wang J Z, Patil V, Ajisebutu A, Gui C, Yefet L S, Ellenbogen Y, Liu J, Mamatjan Y, Wei Q, Singh O, Mansouri S, Ehret F, Capper D, Cohen-Gadol A A, Zadeh G, et al.",https://pubmed.ncbi.nlm.nih.gov/41259653/,"This study developed a framework to use DNA methylation-based models to guide the clinical management of cranial meningioma. The key finding is that patients with high-risk, radiation-sensitive tumors and low-risk, radiation-sensitive tumors can benefit from adjuvant radiation therapy, while those with radiation-resistant tumors do not. This framework can help clinicians make informed decisions about the use of radiation therapy for meningioma patients based on their molecular profile."
41260669,Comparative Evaluation of Deep Learning Models for 3D Segmentation and Volumetry of Vestibular Schwannomas Using Large Heterogeneous Datasets with External Validation.,"3D-segmentation and volumetry of vestibular schwannomas (VS) is a more accurate method to determine tumor growth on serial imaging, but manual annotation is time-consuming to implement in routine clinical practice. We evaluated and compared five deep learning-based segmentation models [nnUNet (base, ResEncL), U-Mamba, UNETR, and MedSAM] for 3D VS segmentation and volumetry, and examined robustness to acquisition heterogeneity and generalization on an external cohort MATERIALS AND METHODS: Our refined Internal dataset consisted of T1-contrast enhanced images, including 2,692 scans (n= 383 patients) for training and 277 scans (n=97 patients) for testing. Post model training and validation, performance was evaluated on both internal, as well as a publicly available external test set (n=241) using Dice similarity coefficient, Hausdorff distance, surfaceto-surface (S2S) distance and relative volume error (RVE). A sub-analysis of the model performance was also performed to evaluate the impact of tumor volumes and dataset heterogeneity.The median Dice score on the external test set varied between 0.899-0.927 with U-Mamba achieving highest performance, followed by nnUNet (base and ResEncL). For these top three models, the median Hausdorff distance was 3.59 mm, while the Hausdorff95 was 1.6 mm. The S2S distance was <1 mm and median RVE (%) varied between 0.07-0.08. Median Dice scores were lower (0.848-0.854) for smaller tumors (<200mm3) and higher for tumors >400 mm3(median Dice score 0.925-0.932).Models based on convolutional neural networks (CNNs), transformer networks as well as foundational models show robust performance for VS segmentation. Given the consistently high performance and self-optimizing frameworks of CNN based models (U-Mamba, nnUNet,), these may be more suitable for clinical applications.VS＝ vestibular schwannoma; CPA＝ cerebello-pontine angle; IAC＝ Internal Auditory Canal; DL＝ Deep-learning; CNN＝ convolutional neural network; SRS＝ stereotactic radiosurgery; RVE＝ relative volume error; OLS＝ ordinary least squares; LMM＝ linear mixed effects models; ANOVA＝ analysis of variance.© 2025 by American Journal of Neuroradiology.",AJNR. American journal of neuroradiology,"Nov 19, 2025",2025,Nov,19,Mehta P M|Yayli S B|Rai P|Sonka M|Blezek D J|Zhang H|Silvera V M|Benson J C|Carlson M L|Erickson B J|Bathla G,Mehta P M|Yayli S B|Rai P|Sonka M|Blezek D J|Zhang H|Silvera V M|Benson J C|Carlson M L|Erickson B J|Bathla G,"From the Department of Radiology, Mayo Clinic, Rochester, MN, USA (P.M.M, S.B.Y, P.R, D.J.B, V.M.S, J.C.B, B.J.E, G.B.), Department of Otology/Neurotology, Mayo Clinic, Rochester, MN, USA (M.L.C), College of Engineering, University of Iowa, Iowa City, IA, USA (M.S, H.Z.), and Department of Radiology, The University of Texas at San Antonio, San Antonio, TX, USA (P.M.M).","Mehta P M, Yayli S B, Rai P, Sonka M, Blezek D J, Zhang H, Silvera V M, Benson J C, Carlson M L, Erickson B J, Bathla G",https://pubmed.ncbi.nlm.nih.gov/41260669/,"This study evaluated and compared five deep learning models for 3D segmentation and volumetry of vestibular schwannomas, a type of brain tumor. The models showed robust performance, with the convolutional neural network-based models, U-Mamba and nnUNet, achieving the highest accuracy. These deep learning models could potentially improve the clinical management of vestibular schwannomas by providing a more accurate and efficient method for tumor measurement and monitoring."
41260670,Photon Counting Detector CT Angiography for Localization of the Artery of Adamkiewicz.,"Photon counting detector CT is a relatively new technology that is becoming increasingly prevalent. In recent years, photon counting CT has been shown to have benefits in numerous neuroradiologic clinical applications, including temporal bone imaging, detection of spinal CSF leaks, and CT angiography of the head, neck, and spine. New uses for photon counting detector CT continue to emerge, capitalizing on the high spatial resolution and other advantages of this technology to improve patient care. One potential application in the spine is the detection and localization of the artery of Adamkiewicz, which provides the dominant supply to the inferior portion of the anterior spinal artery. Localization of this artery is sometimes desired prior to surgeries requiring ligation of the foraminal neurovascular complex. Traditional energy integrating detector CT is useful but imperfect for detection of this relatively small and transiently opacifying vessel. The improved spatial resolution and spectral information obtained with photon counting CT may help improve detection of the artery of Adamkiewicz. In this clinical report, we outline a protocol for imaging the artery of Adamkiewicz with photon counting detector CT and describe a comparative analysis of three different reconstruction techniques in six consecutive patients who underwent this exam. We found that an intermediate sharp vascular kernel (Bv60) reconstructed with a low energy threshold outperformed other conditions, including a sharper kernel and a low keV virtual monoenergetic reconstruction.ABBREVIATIONS: AKA = artery of Adamkiewicz or great radiculomedullary artery; CNR = contrast-to-noise ratio; EID = energy integrating detector; PCD = photon counting detector QIR = quantum iterative reconstruction; T3D = low energy threshold; UHR = ultra-high resolution.© 2025 by American Journal of Neuroradiology.",AJNR. American journal of neuroradiology,"Nov 19, 2025",2025,Nov,19,Madhavan A A|Kranz P G|Kodet M L|Bathla G|Lehman V T|Diehn F E|Mark I T|Yu L|Amrhein T J,Madhavan A A|Kranz P G|Kodet M L|Bathla G|Lehman V T|Diehn F E|Mark I T|Yu L|Amrhein T J,"From the Department of Radiology (A.A.M, M.L.K., G.B., V.T.L., F.E.D., I.T.M., L.Y.), Mayo Clinic, Rochester, MN, USA; Department of Radiology (P.G.K., T.J.A.), Duke Health, Durham, NC, USA.","Madhavan A A, Kranz P G, Kodet M L, Bathla G, Lehman V T, Diehn F E, Mark I T, Yu L, Amrhein T J",https://pubmed.ncbi.nlm.nih.gov/41260670/,"Photon counting detector CT is a new technology that can improve the detection and localization of the artery of Adamkiewicz, a critical blood vessel in the spine. This study found that a specific reconstruction technique using photon counting CT outperformed traditional methods, which could help guide surgical planning and improve patient care."
41261255,Global Dynamics in Cosmetic Tourism.,"Cosmetic tourism is becoming increasingly popular in aesthetic surgery. Some countries more frequently host patients from other countries, while others supply patients. However, longitudinal trends in cosmetic tourism are understudied. This study examined specific patterns in cosmetic tourism growth, market share, and procedure volumes.Data on the number of procedures performed on cosmetic tourists from 2019-2023 was obtained from the International Society of Aesthetic Plastic Surgery public reports. Aesthetic procedure volumes and percentage changes in market share were calculated across all years. Countries were classified as ""pure host,"" ""pure origin,"" or ""hybrid"" countries (i.e., sharing features of both host and origin countries) based on frequency and rank of appearance. Additionally, host countries were grouped into clusters via hierarchical clustering, and differences in procedural volumes were calculated across clusters.The percentage of aesthetic surgery procedures performed on international patients and the percent change in cosmetic tourism volume increased from 2019-2023 (r = 1.00; P < 0.001). Argentina, Brazil, and the United States of America showed the greatest growth in aesthetic procedure volumes and percent change in market share. Most countries were classified as ""hybrid"" countries. Finally, host country clusters significantly varied in the relative number of surgical versus non-surgical procedures performed.Cosmetic tourism continues to gain popularity, with country-specific variations in aesthetic procedure volumes, market share, and surgical versus non-surgical procedure proportions. The majority of countries analyzed were classified as ""hybrid,"" highlighting a complex interplay between patients arriving and leaving to undergo aesthetic surgery.This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors   www.springer.com/00266 .© 2025. Springer Science+Business Media, LLC, part of Springer Nature and International Society of Aesthetic Plastic Surgery.",Aesthetic plastic surgery,"Nov 19, 2025",2025,Nov,19,Sinha K|Lipinski A W|Rames J D|Sharaf B A,Sinha K|Lipinski A W|Rames J D|Sharaf B A,"Mayo Clinic Alix School of Medicine, 5951 E Mayo Blvd, Phoenix, AZ, 85054, USA.|Division of Plastic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA.|Division of Plastic Surgery, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Sharaf.basel@mayo.edu.","Sinha K, Lipinski A W, Rames J D, Sharaf B A",https://pubmed.ncbi.nlm.nih.gov/41261255/,"The study found that cosmetic tourism is increasing globally, with some countries emerging as major hosts for patients from other countries, while others primarily supply patients. The majority of countries were classified as ""hybrid,"" meaning they both host and send patients for aesthetic procedures. The study also identified variations in the types of procedures performed across different host country clusters."
40994023,Guide to the diagnosis of lymphoid neoplasms in blood and bone marrow: A Bone Marrow Pathology Group approach.,"The successful diagnosis and classification of lymphoid neoplasms in blood and bone marrow is the responsibility of the practicing pathologist. This guide provides a general ""roadmap"" for this process, from initial case recognition to final classification.The integration of hematologic, morphologic, immunophenotypic, and genetic features for the full spectrum of precursor and mature B-cell, T-cell, and natural killer-cell neoplasms that typically manifest in blood and bone marrow is included.Classification systems for lymphoid neoplasms provide criteria for pathologists to render a diagnosis that is optimal for patient care, treatment, and outcome prediction.This guide provides diagnostic strategies for lymphoid neoplasms encountered in blood and bone marrow specimens using both the International Consensus Classification and the World Health Organization fifth edition classification systems. Key tips are provided for each entity along with testing requirements, differential diagnosis, nonneoplastic mimics, and other unique features based on the experience of the Bone Marrow Pathology Group members.© The Author(s) 2025. Published by Oxford University Press on behalf of American Society for Clinical Pathology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.",American journal of clinical pathology,"Nov 19, 2025",2025,Nov,19,Foucar K|Bagg A|Arber D A|Bueso-Ramos C E|Geyer J T|Hasserjian R P|Orazi A|Reichard K K|Tam W|Wang S A|Weinberg O K|Hsi E D,Reichard K K|Hsi E D,"Department of Pathology, University of New Mexico, Albuquerque, NM, United States.|Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States.|Department of Pathology, University of Chicago, Chicago, IL, United States.|Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.|Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States.|Department of Pathology, Massachusetts General Hospital, Boston, MA, United States.|Department of Pathology, Texas Tech University, El Paso, TX, United States.|Department of Pathology, Mayo Clinic, Rochester, MN, United States.|Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, Greenvale, NY, United States.|Department of Pathology, University of Texas, Southwestern, Dallas, TX, United States.","Foucar K, Bagg A, Arber D A, Bueso-Ramos C E, Geyer J T, Hasserjian R P, Orazi A, Reichard K K, Tam W, Wang S A, Weinberg O K, Hsi E D",https://pubmed.ncbi.nlm.nih.gov/40994023/,"This medical research provides a comprehensive guide for pathologists to accurately diagnose and classify different types of lymphoid neoplasms in blood and bone marrow samples. The guide integrates various diagnostic features, including hematologic, morphologic, immunophenotypic, and genetic characteristics, to help pathologists make the most appropriate diagnosis for patient care, treatment, and outcome prediction."
